New MenB vaccine approved for use in the US
30 October 2014
Meningitis Research Foundation (MRF) welcomes news that that the potential for protection against meningococcal B infection (MenB) is continuing to advance across the world with today’s announcement that a Pfizer MenB vaccine aimed at 10 – 25 year olds in the US has been licensed. Meningococcal B infection is an important cause of meningitis and septicaemia in the US and has been the leading cause in the UK for decades.
Pfizer’s MenB vaccine, Trumenba® was submitted for accelerated approval earlier this year. It has been approved by the Food and Drug Administration‘s (FDA) Breakthrough Therapy Designation and Priority Review programme so that Pfizer will continue to complete ongoing studies around the vaccine’s effectiveness . This license means that the vaccine can now be used in the US, and considered for use in the immunisation programme.
MRF Chief Executive, Christopher Head said: “We are delighted to see yet another part of the world taking action to protect against MenB. This accelerated approval demonstrates just how seriously America views MenB, especially after worrying outbreaks of the disease at some of its universities.
“But the UK has had a licensed MenB vaccine, Bexsero®, since January 2013 and a national programme to immunise infants was recommended in March this year. The UK was leading the world in its desire to protect against this deadly disease and it’s frustrating that nearly two years on we still don’t know when the UK Government will make the vaccine freely available on the NHS and start rolling out a MenB vaccination programme.”
More on MenB
In-depth Q + A on the vaccine
Hi, I’m Sam and I’m MRF's PR Manager.
If you want to know more about this story call me on 0333 405 626251, out of office hours on 07875 498047 or email firstname.lastname@example.org